Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled Trials

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Bonovas, Stefanos ^a,b,c   Nikolopoulos, Georgios K ^b   Bagos, Pantelis G ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Centre for Disease Control and Prevention   (Greece)

^c UNIVERSITY OF CENTRAL GREECE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; CLOFIBRIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PLACEBO;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; COLON CANCER; CONFIDENCE INTERVAL; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT CANCER; SYSTEMATIC REVIEW; UROGENITAL TRACT CANCER;

ADULT; AGED; CARDIOVASCULAR DISEASES; DATABASES, BIBLIOGRAPHIC; FEMALE; FIBRIC ACIDS; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SURVIVAL RATE;

SCOPUS;

EID: 84866532524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045259     Document Type: Article

References (66)

1. Staels B, Fruchart JC, (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470.
2. Després JP, Lemieux I, Robins SJ, (2004) Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 64: 2177-2198.
3. WHO Cooperative Trial Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40: 1069-1118.
4. WHO Cooperative Trial Committee of Principal Investigators (1985) WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2: 379-385.
5. Heady JA, Morris JN, Oliver MF, (1992) WHO clofibrate/cholesterol trial: clarifications. Lancet 340: 1405-1406.
6. Newman TB, Hulley SB, (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275: 55-60.
7. Dalen JE, Dalton WS, (1996) Does lowering cholesterol cause cancer? JAMA 275: 67-69.
8. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, et al. (2011) Use of fibrates in the United States and Canada. JAMA 305: 1217-1224.
9. Greenland S, (1994) Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140: 290-296.
10. Jüni P, Witschi A, Bloch R, Egger M, (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282: 1054-1060.
11. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
12. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
13. Cochran WG, (1954) The combination of estimates from different experiments. Biometrics 8: 101-129.
14. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
16. Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration.
17. Sharp S, (1998) Meta-analysis regression. Stata Tech Bull 42: 16-24.
18. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA, (1995) A random-effects regression model for meta-analysis. Stat Med 14: 395-411.
19. Thompson SG, Sharp SJ, (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693-2708.
20. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W64.
21. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574.
22. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, et al. (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347: 849-853.
23. Begg TB, Rifkind BM, (1971) Evaluation of clofibrate therapy in peripheral arteriopathy. Minerva Med 62: 3469-3475.
24. The BIP Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27.
25. The Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360-381.
26. Diabetes Atherosclerosis Intervention Study Investigators, (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905-910.
27. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, et al. (1991) Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14: 308-317.
28. Keech A, Simes RJ, Barter P, Best J, Scott R, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849-1861.
29. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, et al. (1994) The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 235: 31-39.
30. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Mänttäri M, et al. (1993) Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 25: 41-45.
31. Meade T, Zuhrie R, Cook C, Cooper J, (2002) Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 325: 1139.
32. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, et al. (1997) Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96: 2137-2143.
33. Group of physicians of the Newcastle upon Tyne region (1971) Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study. Br Med J 4: 767-775.
34. Research Committee of the Scottish Society of Physicians (1971) Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J 4: 775-784.
35. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, et al. (1998) Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21: 641-648.
36. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341: 410-418.
37. Acheson J, Hutchinson EC, (1972) Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 15: 177-183.
38. Cullen JF, Town SM, Campbell CJ, (1972) Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 94: 554-562.
39. The Veterans Administration Cooperative Study Group (1973) The treatment of cerebrovascular disease with clofibrate. Stroke 4: 684-693.
40. The Coronary Drug Project Research Group (1978) Estrogens and cancer. JAMA 239: 2758-2759.
41. Dewar HA, (1972) Trial of clofibrate. Br Med J 2: 228.
42. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, et al. (2006) Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 98: 1538-1546.
43. Saha SA, Arora RR, (2010) Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 141: 157-166.
44. Tenenbaum A, Boyko V, Fisman EZ, Goldenberg I, Adler Y, et al. (2008) Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? Cardiovasc Diabetol 7: 18.
45. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, et al. (2009) Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 122: 962.e1-8.
46. Jun M, Foote C, Lv J, Neal B, Patel A, et al. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375: 1875-1884.
47. Muldoon MF, Manuck SB, Matthews KA, (1990) Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301: 309-314.
48. Oliver MF, (1991) Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet 337: 1529-1531.
49. Hulley SB, Walsh JM, Newman TB, (1992) Health policy on blood cholesterol. Time to change directions. Circulation 86: 1026-1029.
50. Davey Smith G, Pekkanen J, (1992) Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304: 431-434.
51. Pedersen T, (2009) Lipid-lowering drugs and risk for cancer. Curr Atheroscler Rep 11: 350-357.
52. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM, (2006) Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24: 4808-4817.
53. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 7: e29849.
54. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM, (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23: 8606-8612.
55. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM, (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million subjects. J Clin Oncol 25: 3462-3468.
56. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, et al. (2010) Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 25: 29-35.
57. Bonovas S, Filioussi K, Sitaras NM, (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103: 2646-2651.
58. Bonovas S, Filioussi K, Sitaras NM, (2008) Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123: 899-904.
59. Bonovas S, Filioussi K, Tsantes A, Sitaras NM, (2007) Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 64: 255-262.
60. Olsen J, Johansen C, Sørensen H, McLaughlin J, Mellemkjaer L, et al. (1999) Lipid-lowering medication and risk of cancer. J Clin Epidemiol 52: 167-169.
61. Blais L, Desgagné A, LeLorier J, (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368.
62. Murtola TJ, Tammela TL, Lahtela J, Auvinen A, (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 2226-2232.
63. Fortuny J, de Sanjosé S, Becker N, Maynadié M, Cocco PL, et al. (2006) Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15: 921-925.
64. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192.
65. Gardette V, Bongard V, Dallongeville J, Arveiler D, Bingham A, et al. (2009) Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol 103: 381-386.
66. Davey Smith G, Ebrahim S, (2002) Data dredging, bias, or confounding. BMJ 325: 1437-1438.